Behbahani Ali
SEC CIK 1613867 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | Dir | 110.2K | $5.00M | — | 22 | 2021-09-17 | 2026-09-18 |
| CRSP | CRISPR Therapeutics AG | Dir | 30.3K | — | $780.9K | 4 | 2025-08-06 | 2026-09-17 |
| GLUE | Monte Rosa Therapeutics, Inc. | Dir | 0 | — | — | 1 | 2026-07-01 | 2026-07-01 |
| KRRO | Korro Bio, Inc. | Dir, 10% | 1.30M | — | — | 3 | 2023-11-03 | 2026-03-10 |
| SGP | SpyGlass Pharma, Inc. | Dir, 10% | 955.0K | $15.00M | — | 2 | 2026-02-09 | 2026-02-09 |
| MBX | MBX Biosciences, Inc. | 10% | 1.02M | $8.00M | — | 2 | 2024-09-16 | 2024-09-16 |
| CVRX | CVRx, Inc. | Dir | 316 | — | — | 1 | 2023-12-14 | 2023-12-14 |
| SVRA | Savara Inc | 10% | 24.47M | $1000.0K | — | 1 | 2023-07-17 | 2023-07-17 |
| MIRM | Mirum Pharmaceuticals, Inc. | 10% | 30.0K | — | — | 1 | 2023-06-13 | 2023-06-13 |
| TRVI | Trevi Therapeutics, Inc. | 10% | 948.9K | $6.80M | — | 2 | 2021-10-18 | 2022-04-11 |
Most active insiders at BDTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Raman Prakash | Dir | — | — |
| 2 | Behbahani Ali | Dir | — | — |
Transactions 39
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-21 18:40 | 2026-09-17 | CRSP | CRISPR Therapeutics AG | Behbahani Ali | Dir | M - OptEx | $14.00 | +30.0K | 30.3K | +9,494% | +$420.0K |
| D | 2026-09-21 18:40 | 2026-09-17 | CRSP | CRISPR Therapeutics AG | Behbahani Ali | Dir | S - Sale+OE | $57.09 | -13.7K | 16.6K | -45% | -$780.9K |
| 2026-09-21 18:30 | 2025-08-06 | CRSP | CRISPR Therapeutics AG | Behbahani Ali | Dir | J - Other | $0.00 | +60 | 316 | +23% | $0 | |
| I | 2026-09-21 18:30 | 2025-08-06 | CRSP | CRISPR Therapeutics AG | Behbahani Ali | Dir | J - Other | $0.00 | +15 | 29 | +107% | $0 |
| 2026-09-21 17:45 | 2026-09-18 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $1.93 | +7,707 | 110.2K | +8% | +$14.9K | |
| MI | 2026-07-06 17:57 | 2026-07-01 | GLUE | Monte Rosa Therapeutics, Inc. | Behbahani Ali | Dir | J - Other | $0.00 | -1.00M | 0 | -100% | $0 |
| 2026-06-22 16:19 | 2026-06-19 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $1.66 | +8,961 | 102.5K | +10% | +$14.9K | |
| 2026-03-20 | 2026-03-20 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.15 | +6,919 | 93.6K | +8% | +$14.9K | |
| DI | 2026-03-12 | 2026-03-10 | KRRO | Korro Bio, Inc. | Behbahani Ali | Dir, 10% | A - Grant | $11.11 | +207.1K | 1.30M | +19% | +$2.30M |
| DMI | 2026-02-11 | 2026-02-09 | SGP | SpyGlass Pharma, Inc. | Behbahani Ali | Dir, 10% | C - Cnv Deriv | — | +6.45M | 955.0K | New | — |
| DI | 2026-02-11 | 2026-02-09 | SGP | SpyGlass Pharma, Inc. | Behbahani Ali | Dir, 10% | P - Purchase | $16.00 | +937.5K | 6.04M | +18% | +$15.00M |
| 2025-12-15 | 2025-12-12 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.76 | +5,208 | 86.6K | +6% | +$14.4K | |
| 2025-09-22 | 2025-09-19 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $3.35 | +4,291 | 81.4K | +6% | +$14.4K | |
| 2025-06-20 | 2025-06-20 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.33 | +6,170 | 77.2K | +9% | +$14.4K | |
| 2025-03-21 | 2025-03-21 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $1.88 | +7,646 | 71.0K | +12% | +$14.4K | |
| 2024-12-16 | 2024-12-13 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.50 | +5,750 | 63.3K | +10% | +$14.4K | |
| 2024-09-20 | 2024-09-20 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $4.78 | +3,007 | 57.6K | +6% | +$14.4K | |
| DMI | 2024-09-17 | 2024-09-16 | MBX | MBX Biosciences, Inc. | Behbahani Ali | 10% | C - Cnv Deriv | — | +3.11M | 1.02M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | MBX Biosciences, Inc. | Behbahani Ali | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| 2024-06-21 | 2024-06-21 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $4.98 | +2,887 | 54.6K | +6% | +$14.4K | |
| I | 2024-04-24 | 2024-04-22 | KRRO | Korro Bio, Inc. | Behbahani Ali | Dir, 10% | A - Grant | $56.00 | +17.9K | 1.09M | +2% | +$1000.0K |
| 2024-04-03 | 2024-03-15 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $4.54 | +3,166 | 51.7K | +7% | +$14.4K | |
| D | 2023-12-18 | 2023-12-14 | CVRX | CVRx, Inc. | Behbahani Ali | Dir | M - OptEx | $0.24 | +316 | 316 | New | +$75.84 |
| 2023-12-15 | 2023-12-15 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.73 | +4,455 | 48.5K | +10% | +$12.2K | |
| DI | 2023-11-07 | 2023-11-03 | KRRO | Korro Bio, Inc. | Behbahani Ali | Dir, 10% | A - Grant | — | +1.07M | 1.07M | New | — |
| 2023-09-18 | 2023-09-15 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $3.60 | +3,299 | 44.1K | +8% | +$11.9K | |
| I | 2023-07-19 | 2023-07-17 | SVRA | Savara Inc | Behbahani Ali | 10% | P - Purchase | $3.00 | +333.3K | 24.47M | +1% | +$1000.0K |
| I | 2023-07-06 | 2023-07-05 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | P - Purchase | $5.00 | +1.00M | 4.45M | +29% | +$5.00M |
| 2023-06-16 | 2023-06-16 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.10 | +5,655 | 40.8K | +16% | +$11.9K | |
| MI | 2023-06-15 | 2023-06-13 | MIRM | Mirum Pharmaceuticals, Inc. | Behbahani Ali | 10% | J - Other | $0.00 | -2.00M | 30.0K | -99% | $0 |
| 2023-03-20 | 2023-03-16 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $1.67 | +7,111 | 35.1K | +25% | +$11.9K | |
| 2022-12-19 | 2022-12-16 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $1.50 | +7,917 | 28.0K | +39% | +$11.9K | |
| 2022-09-19 | 2022-09-16 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.62 | +4,532 | 20.1K | +29% | +$11.9K | |
| 2022-06-17 | 2022-06-17 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $2.03 | +5,850 | 15.6K | +60% | +$11.9K | |
| DMI | 2022-04-13 | 2022-04-11 | TRVI | Trevi Therapeutics, Inc. | Behbahani Ali | 10% | P - Purchase | $1.90 | +3.58M | 948.9K | New | +$6.80M |
| 2022-03-18 | 2022-03-18 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $3.02 | +4,346 | 9,705 | +81% | +$13.1K | |
| 2021-12-17 | 2021-12-17 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $5.31 | +2,472 | 5,359 | +86% | +$13.1K | |
| DI | 2021-10-19 | 2021-10-18 | TRVI | Trevi Therapeutics, Inc. | Behbahani Ali | 10% | P - Purchase | — | +1.85M | 7.79M | +31% | — |
| 2021-09-23 | 2021-09-17 | BDTX | Black Diamond Therapeutics, Inc. | Behbahani Ali | Dir | A - Grant | $9.90 | +1,326 | 2,887 | +85% | +$13.1K |
Purchase Sale Sale after option exercise All abbreviations